Real Life Prospective Evaluation of New Drug-Eluting Platform for Chemoembolization of Patients with Hepatocellular Carcinoma: PARIS Registry.

Thierry de BaèreBoris GuiuMaxime RonotPatrick ChevallierGéraldine SergentIllario TancrediLambros TselikasMarco Dioguardi BurgioLucas RaynaudFrederic DeschampsGontran Verset

Published in: Cancers (2020)

DEM-TACE using LifePearlTM provides a high tumor response rate in HCC patients. HBT rates within or below previously reported results for cTACE and DEM-TACE indicate a good safety profile for LifePearlTM. The trial was registered in ClinicalTrials.gov National Library of Medicine (ID: NCT03053596).

Keyphrases

end stage renal disease
ejection fraction
newly diagnosed
chronic kidney disease
peritoneal dialysis
clinical trial
prognostic factors
study protocol
randomized controlled trial
quality improvement
phase iii
phase ii
single cell
radiofrequency ablation
liver metastases